

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Maurice ZAUDERER

Appl. No.: 09/966,746

Filed: October 1, 2001

For: **Method of Screening for
Therapeutics for Infectious Diseases**

Confirmation No.: 3613

Art Unit: 1648

Examiner: LUCAS, Z.

Atty. Docket: 1821.0060001/EKS/HCC

**Second Supplemental Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(d)**

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicant's First Supplemental Information Disclosure Statement filed on May 17, 2004, in connection with the above-captioned application.

A copy of document **AR16** is submitted herewith. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **AB2-AF2**, cited on the attached Form PTO-1449 are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached PTO-1449 based on

information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Second Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Enclosed find our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: October 17, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

415840_1.DOC



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

1821.0060001/EKS/HCC

APPLICATION NO.

09/966,746

FIRST NAMED INVENTOR

Maurice ZAUDERER

FILING DATE

October 1, 2001

ART UNIT

1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB2	6,706,477 B2	03/16/2004	Zauderer			04/02/2001
	AC2	6,800,442 B2	10/05/2004	Zauderer			01/03/2002
	AD2	6,872,518 B2	03/29/2005	Zauderer			09/22/1997
	AE2	2003/0194696 A1	10/16/2003	Zauderer and Smith			10/22/2002
	AF2	2003/0022157 A1	01/30/2003	Zauderer and Smith			03/28/2001
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	16	Könen-Waisman, S., <i>et al.</i> , "Self Heat-Shock Protein (hsp60) Peptide Serves in a Conjugate Vaccine against a Lethal Pneumococcal Infection," <i>J. Infect. Dis.</i> 179:403-413, University of Chicago Press (February 1999)
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.